C R Bard Inc (BCR) : Hikari Power Ltd has sold out all of its stake in C R Bard Inc during the most recent quarter, according to the disclosure filed by the company on Aug 3, 2016 with the SEC. The investment management company has sold out 3,420 shares of C R Bard Inc which is valued at $751,819.
Other Hedge Funds, Including , Compass Capital Management Inc reduced its stake in BCR by selling 4,339 shares or 4.27% in the most recent quarter. The Hedge Fund company now holds 97,243 shares of BCR which is valued at $21,756,176. C R Bard Inc makes up approx 4.06% of Compass Capital Management Inc’s portfolio.Davis R M Inc reduced its stake in BCR by selling 4,246 shares or 2.21% in the most recent quarter. The Hedge Fund company now holds 187,911 shares of BCR which is valued at $43,574,682. C R Bard Inc makes up approx 2.09% of Davis R M Inc’s portfolio.
C R Bard Inc closed down -1.06 points or -0.48% at $221.46 with 3,28,066 shares getting traded on Monday. Post opening the session at $222.19, the shares hit an intraday low of $220.61 and an intraday high of $222.77 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
On the company’s financial health, C R Bard Inc reported $2.34 EPS for the quarter, beating the analyst consensus estimate by $ 0.17 according to the earnings call on Apr 27, 2016. Analyst had a consensus of $2.17. The company had revenue of $873.50 million for the quarter, compared to analysts expectations of $847.53 million. The company’s revenue was up 6.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.10 EPS.
Many Wall Street Analysts have commented on C R Bard Inc. Company shares were Reiterated by Deutsche Bank on Jul 27, 2016 to “Hold”, Firm has raised the Price Target to $ 240 from a previous price target of $234 .Company shares were Reiterated by Barclays on Jul 27, 2016 to “Equal Weight”, Firm has raised the Price Target to $ 235 from a previous price target of $224 .C R Bard Inc was Downgraded by BofA/Merrill to ” Neutral” on Jul 8, 2016.
C. R. Bard Inc. (Bard) and its subsidiaries are engaged in the design manufacture packaging distribution and sale of medical surgical diagnostic and patient care devices. . The Company reports its sales in four major product group categories: vascular urology oncology and surgical specialty. The Company also has a product group of other products. The Company’s vascular products cover a range of minimally invasive devices for the treatment of peripheral vascular disease and heart arrhythmias. Its urology products include basic urology drainage products fecal and urinary continence products urological specialty products and Targeted Temperature Management products. Its oncology products cover a range of devices used in the treatment and management of various cancers and other diseases and disorders. Its surgical specialty products include implanted patches and fixation devices for hernia and other soft tissue repairs in addition to hemostats and surgical sealants.